DE60032622D1 - Zusammensetzung und verfahren zur krebs-antigen-immuntherapie - Google Patents

Zusammensetzung und verfahren zur krebs-antigen-immuntherapie

Info

Publication number
DE60032622D1
DE60032622D1 DE60032622T DE60032622T DE60032622D1 DE 60032622 D1 DE60032622 D1 DE 60032622D1 DE 60032622 T DE60032622 T DE 60032622T DE 60032622 T DE60032622 T DE 60032622T DE 60032622 D1 DE60032622 D1 DE 60032622D1
Authority
DE
Germany
Prior art keywords
patient
lymphocytes
composition
effector
cancer antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032622T
Other languages
English (en)
Other versions
DE60032622T2 (de
Inventor
Gary W Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TVAX Biomedical LLC
Original Assignee
TVAX Biomedical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TVAX Biomedical LLC filed Critical TVAX Biomedical LLC
Application granted granted Critical
Publication of DE60032622D1 publication Critical patent/DE60032622D1/de
Publication of DE60032622T2 publication Critical patent/DE60032622T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60032622T 1999-10-05 2000-10-05 Zusammensetzung und verfahren zur krebs-antigen-immuntherapie Expired - Lifetime DE60032622T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/412,681 US6406699B1 (en) 1999-10-05 1999-10-05 Composition and method of cancer antigen immunotherapy
US412681 1999-10-05
PCT/US2000/027399 WO2001024771A1 (en) 1999-10-05 2000-10-05 Composition and method of cancer antigen immunotherapy

Publications (2)

Publication Number Publication Date
DE60032622D1 true DE60032622D1 (de) 2007-02-08
DE60032622T2 DE60032622T2 (de) 2007-12-20

Family

ID=23634000

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032622T Expired - Lifetime DE60032622T2 (de) 1999-10-05 2000-10-05 Zusammensetzung und verfahren zur krebs-antigen-immuntherapie

Country Status (11)

Country Link
US (2) US6406699B1 (de)
EP (1) EP1225870B1 (de)
AT (1) ATE349198T1 (de)
AU (1) AU7856700A (de)
CA (1) CA2388221C (de)
CY (1) CY1106400T1 (de)
DE (1) DE60032622T2 (de)
DK (1) DK1225870T3 (de)
ES (1) ES2279772T3 (de)
PT (1) PT1225870E (de)
WO (1) WO2001024771A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350597A1 (en) * 1998-12-02 2000-06-08 Barbara Ann Foster Methods and compositions for restoring conformational stability of a protein of the p53 family
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
EP1368061B1 (de) * 2000-10-20 2008-12-24 Tsuneya Ohno Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US6977072B2 (en) 2000-10-27 2005-12-20 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
AU2002362072A1 (en) 2001-12-07 2003-06-23 Board Of Regents The University Of Texas System Use a parapox b2l protein to modify immune responses to administered antigens
JP2006507214A (ja) * 2002-02-22 2006-03-02 イントラセル・リソーシーズ・エル・エル・シー 無菌の、免疫原性の、非腫瘍形成性の腫瘍細胞組成物及び方法
CN100579577C (zh) * 2002-03-15 2010-01-13 退伍军人事务研发服务部 使用细胞脱唾液酸决定簇和糖缀合物将细胞靶向组织和器官的方法和组合物
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004003142A2 (en) * 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US7745157B2 (en) * 2003-02-21 2010-06-29 University Of Maryland, Baltimore Human lymphocyte medium adjuvant
DK2234642T3 (en) 2007-11-28 2018-01-08 Irx Therapeutics Inc PROCEDURE FOR INCREASING AN IMMUNOLOGICAL EFFECT
US20110319871A1 (en) * 2009-03-09 2011-12-29 Tvax Biomedical, Llc Infectious disease cellular immunotherapy
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
CA2902448C (en) 2013-03-01 2023-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood
EP3851110A1 (de) 2015-05-28 2021-07-21 Kite Pharma, Inc. Verfahren zur konditionierung von patienten für eine t-zell-therapie
PT3302507T (pt) 2015-05-28 2023-05-23 Kite Pharma Inc Métodos de diagnóstico para terapia com células t
EP3347473A4 (de) * 2015-09-09 2019-04-10 Tvax Biomedical I, LLC Verfahren zur kombination von adoptiver t-zelltherapie mit onkolytischer viruszusatztherapie
JP6952029B2 (ja) 2015-10-20 2021-10-20 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｔ細胞療法用のｔ細胞を調製する方法
US11781112B2 (en) * 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
EP3984559A1 (de) 2016-04-01 2022-04-20 Kite Pharma, Inc. Chimäre antigen- und t-zell-rezeptoren und ihre anwendungsverfahren
CN117903307A (zh) 2016-04-01 2024-04-19 凯德药业股份有限公司 Bcma结合分子及其使用方法
RS63735B1 (sr) 2016-04-01 2022-12-30 Kite Pharma Inc Himerni receptori i postupci njihove upotrebe
WO2018106958A1 (en) * 2016-12-07 2018-06-14 Transtarget, Inc. Methods and compositions for vaccinating and boosting cancer patients
ES2900233T3 (es) 2017-02-14 2022-03-16 Kite Pharma Inc Moléculas que se unen a CD70 y métodos de uso de las mismas
TW201837175A (zh) 2017-03-13 2018-10-16 美商凱特製藥公司 用於黑色素瘤之嵌合抗原受體及其用途
EP3490605B1 (de) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Ersatz von zytotoxischer vorbehandlung vor einer zellulären immuntherapie
CN110494158A (zh) 2017-04-03 2019-11-22 凯德药业股份有限公司 使用包含优化的多功能t细胞的嵌合受体t细胞进行治疗
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
TW201900870A (zh) 2017-05-26 2019-01-01 美商凱特製藥公司 製備和使用胚胎間充質先驅細胞的方法
CN114533863A (zh) * 2017-09-15 2022-05-27 凯德药业股份有限公司 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统
CA3076099A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. Linkers for chimeric antigen receptors
KR20200071753A (ko) 2017-10-18 2020-06-19 카이트 파마 인코포레이티드 키메라 항원 수용체 면역요법제를 투여하는 방법
EP3710471A1 (de) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modifizierte chimäre antigenrezeptoren und verfahren zur verwendung
JP2021510738A (ja) 2018-01-15 2021-04-30 ファイザー・インク ４−１ｂｂと組み合わせたキメラ抗原受容体免疫治療製品の投与方法
US20200390814A1 (en) 2018-02-02 2020-12-17 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
SG11202007513PA (en) 2018-02-16 2020-09-29 Kite Pharma Inc Modified pluripotent stem cells and methods of making and use
TWI723374B (zh) 2018-04-12 2021-04-01 美商凱特製藥公司 利用腫瘤微環境之特性之嵌合受體t細胞治療
KR102544086B1 (ko) 2018-06-01 2023-06-16 카이트 파마 인코포레이티드 키메라 항원 수용체 t 세포 요법
WO2019243888A1 (en) 2018-06-22 2019-12-26 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
CN112533953A (zh) 2018-08-02 2021-03-19 凯德药业股份有限公司 嵌合抗原受体疗法t细胞扩增动力学及其用途
EP3488851A1 (de) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapien
EP3632446B3 (de) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapien
US20220128562A1 (en) * 2018-11-26 2022-04-28 Dana-Farber Cancer Institute, Inc. Biomarkers predictive of cancer cell response to ml329 or a derivative thereof
WO2020113098A1 (en) 2018-11-29 2020-06-04 Vineti Inc. Centralized and decentralized individualized medicine platform
JP7386382B2 (ja) 2018-12-12 2023-11-27 カイト ファーマ インコーポレイテッド キメラ抗原受容体及びｔ細胞受容体並びに使用方法
US11321652B1 (en) 2019-02-20 2022-05-03 Vineti Inc. Smart label devices, systems, and methods
BR112021021996A2 (pt) 2019-05-03 2022-01-11 Kite Pharma Inc Métodos para administração de imunoterapia com receptores de antígeno quimérico
EP3986922A2 (de) 2019-06-21 2022-04-27 Kite Pharma, Inc. Tgf-beta-rezeptoren und verwendungsverfahren
BR112022003852A2 (pt) 2019-09-03 2022-05-31 Allogene Therapeutics Inc Métodos de preparação de células t para terapia de células t
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
AU2021326504A1 (en) 2020-08-14 2023-02-23 Kite Pharma, Inc Improving immune cell function
EP4204545A2 (de) 2020-08-25 2023-07-05 Kite Pharma, Inc. T-zellen mit verbesserter funktionalität
CN116528879A (zh) 2020-10-28 2023-08-01 凯德药业股份有限公司 用于表征t细胞杂质的流式细胞术方法
KR20230124656A (ko) 2020-12-24 2023-08-25 카이트 파마 인코포레이티드 전립선암 키메라 항원 수용체
KR20230129485A (ko) 2021-01-10 2023-09-08 카이트 파마 인코포레이티드 T 세포 요법
CA3211006A1 (en) 2021-02-20 2022-08-25 Kite Pharma, Inc. Gene markers for sellecting immunotherapies
US20220289815A1 (en) 2021-03-11 2022-09-15 Kite Pharma, Inc. Immune cell function
IL307384A (en) 2021-04-16 2023-11-01 Kite Pharma Inc Molecules with a dual link to TACI and BCMA
WO2022221126A1 (en) 2021-04-16 2022-10-20 Kite Pharma, Inc. Methods and systems for scheduling a patient-specific immunotherapy procedure
CA3217354A1 (en) 2021-05-14 2022-11-17 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
CA3221231A1 (en) 2021-05-24 2022-12-01 Kite Pharma, Inc. Chimeric antigen receptor
WO2022261061A1 (en) 2021-06-08 2022-12-15 Kite Pharma, Inc. Gpc3 binding molecules
US20230027004A1 (en) 2021-07-01 2023-01-26 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
WO2023278619A1 (en) 2021-07-02 2023-01-05 Kite Pharma, Inc. A method for identifying variants in gene products from gene constructs used in cell therapy applications
US20230060292A1 (en) 2021-07-26 2023-03-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
EP4377694A1 (de) 2021-07-30 2024-06-05 Kite Pharma, Inc. Überwachung und verwaltung von durch zelltherapie induzierten toxizitäten
US11615874B1 (en) 2021-09-30 2023-03-28 Vineti Inc. Personalized medicine and therapies platform
KR20240099280A (ko) 2021-10-18 2024-06-28 카이트 파마 인코포레이티드 키메라 항원 수용체에 대한 신호전달 도메인
US20230296610A1 (en) 2022-02-15 2023-09-21 Kite Pharma, Inc. Predicting adverse events from immunotherapy
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
WO2024092152A1 (en) 2022-10-28 2024-05-02 Kite Pharma, Inc. Improving efficacy and durable response of immunotherapy
TW202417643A (zh) 2022-10-28 2024-05-01 美商凱特製藥公司 用於將免疫療法最佳化之因素
WO2024196689A1 (en) 2023-03-17 2024-09-26 Kite Pharma, Inc. Impact of tumor microenvironment on efficacy of immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
WO1988000970A2 (en) 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5290551A (en) 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
US5725855A (en) 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
MX9304089A (es) 1992-07-08 1994-01-31 Schering Corp Uso de gm-csf como una vacuna adyuvante.
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
JP2001520509A (ja) * 1995-07-25 2001-10-30 セルセラピー・インコーポレイテツド 自己免疫細胞療法：細胞組成物、方法およびヒト疾患の治療への応用

Also Published As

Publication number Publication date
US20020006409A1 (en) 2002-01-17
DE60032622T2 (de) 2007-12-20
PT1225870E (pt) 2007-06-11
ES2279772T3 (es) 2007-09-01
EP1225870B1 (de) 2006-12-27
EP1225870A1 (de) 2002-07-31
ATE349198T1 (de) 2007-01-15
CA2388221A1 (en) 2001-04-12
CA2388221C (en) 2007-12-04
US6406699B1 (en) 2002-06-18
WO2001024771A1 (en) 2001-04-12
CY1106400T1 (el) 2011-10-12
DK1225870T3 (da) 2007-05-07
AU7856700A (en) 2001-05-10
EP1225870A4 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
ATE349198T1 (de) Zusammensetzung und verfahren zur krebs-antigen- immuntherapie
US5030621A (en) Shed melanoma antigen compositions
DK0585943T3 (da) Opløselige ligander for CD40
ID22689A (id) Metode untuk mengaktifkan sel-sel yang menunjukan-sifat antigen manusia, sel-sel teraktifkan yang menunjukan sifat antigen manusia, dan penggunaannya
WO2002034205A3 (en) Using heat shock proteins to increase immune response
TR200103581T2 (tr) Graft versus host hastalığı tedavisinde CD20' ye karşı antikorların kullanımı.
EP0719150A4 (de) Zellulärer impfstoff und verwendungsmethoden für die behandlung von malignen, soliden tumoren
BR9811037A (pt) Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
US7402317B2 (en) Anti-cancer vaccine
WO1999003976A3 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
US5194384A (en) Method for preparing human meloma vaccine
Gregoire et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia
WO2003090687A8 (en) Using heat shock proteins to increase immune response
HUP0204216A2 (en) A new use of antibodies as vaccines
WO2005009397A3 (en) Human lymphocyte vaccine adjuvant
CA2754109A1 (en) Infectious disease cellular immunotherapy
RU2000122041A (ru) Способ лечения злокачественных опухолей головного мозга
NL192326B (nl) Werkwijze voor het bereiden van een geneesmiddel, waarbij een gezuiverd, ontgift endotoxine samen met een drager en eventueel andere toevoegingen in een voor therapeutische toediening geschikte vorm wordt gebracht.
RU2000111634A (ru) Способ комбинированной иммунотерапии злокачественных опухолей головного мозга
MX9604099A (es) Inmunoterapia de cancer con linfocitos alogenicos.
DE50305753D1 (de) Verfahren und mittel zur prävention, hemmung und therapie von krebserkrankungen
Prescott New therapeutic approaches for treating lymphomas
UA38574A (uk) Спосіб лікування злоякісної пухлини
RU93004625A (ru) Способы лечения, противоопухолевые агенты

Legal Events

Date Code Title Description
8364 No opposition during term of opposition